gemfibrozil trial summary

Atrial fibrillation

Patients without history of AF (primary prevention): 1 trials - VA HIT (AF ancillary study)

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
atrial fibrillation	1.07 [0.75 1.55]	p=1.00	0	2130	1	VA HIT (AF ancillary study),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Cardiovascular prevention

All chronical situations: 3 trials - VA-HIT - Helsinki (HHS) - LOCAT

gemfibrozil vs placebo

No demonstrated result

suggested cardiovascular events by 22% (not demonstrated)

suggested Coronary event by 23% (not demonstrated)

suggested Non fatal MI by 25% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	0.78 [0.65 0.94]	p=0.04	0	2531	1	VA-HIT,
Cardiovascular death	no data
stroke (fatal and non fatal)	0.76 [0.54 1.09]	p=1.00	0	2531	1	VA-HIT,
Coronary event	0.77 [0.65 0.91]	p=0.04	0	7007	3	VA-HIT,Helsinki (HHS),LOCAT,
Coronary death and non fatal MI	no data
Coronary death	0.78 [0.60 1.02]	p=1.00	0	6612	2	VA-HIT,Helsinki (HHS),
cardiac death	0.78 [0.60 1.02]	p=1.00	0	6612	2	VA-HIT,Helsinki (HHS),
MACE	no data
Non fatal MI	0.75 [0.61 0.91]	p=0.04	0	6612	2	VA-HIT,Helsinki (HHS),
All cause death	0.92 [0.77 1.12]	p=1.00	0	6612	2	VA-HIT,Helsinki (HHS),
non cardiovascular death	1.13 [0.87 1.46]	p=1.00	0	6612	2	VA-HIT,Helsinki (HHS),
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.90 [0.63 1.31]	p=1.00	0	6612	2	VA-HIT,Helsinki (HHS),
Rhabdomyolysis	no data
Myopathy	no data
Cancer	0.91 [0.70 1.17]	p=1.00	0	2531	1	VA-HIT,
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

All type of patients: 4 trials - VA-HIT - Helsinki (HHS) - HHS (Frick)(secondary prev subgroup) - LOCAT

gemfibrozil vs placebo

No demonstrated result

suggested cardiovascular events by 22% (not demonstrated)

suggested Coronary event by 23% (not demonstrated)

suggested Non fatal MI by 25% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	0.78 [0.65 0.94]	p=0.04	0	2531	1	VA-HIT,
Cardiovascular death	no data
stroke (fatal and non fatal)	0.76 [0.54 1.09]	p=1.00	0	2531	1	VA-HIT,
Coronary event	0.77 [0.65 0.91]	p=0.04	0	7007	3	VA-HIT,Helsinki (HHS),LOCAT,
Coronary death and non fatal MI	no data
Coronary death	0.78 [0.60 1.02]	p=1.00	0	6612	2	VA-HIT,Helsinki (HHS),
cardiac death	0.85 [0.66 1.10]	p=1.00	0	7240	3	VA-HIT,Helsinki (HHS),HHS (Frick)(secondary prev subgroup),
MACE	no data
Non fatal MI	0.75 [0.61 0.91]	p=0.04	0	6612	2	VA-HIT,Helsinki (HHS),
All cause death	0.96 [0.80 1.15]	p=1.00	0	7240	3	VA-HIT,Helsinki (HHS),HHS (Frick)(secondary prev subgroup),
non cardiovascular death	1.11 [0.86 1.43]	p=1.00	0	7240	3	VA-HIT,Helsinki (HHS),HHS (Frick)(secondary prev subgroup),
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.90 [0.63 1.31]	p=1.00	0	6612	2	VA-HIT,Helsinki (HHS),
Rhabdomyolysis	no data
Myopathy	no data
Cancer	0.91 [0.70 1.17]	p=1.00	0	2531	1	VA-HIT,
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Diabetic patients : 2 trials - HHS (diabetic sub group) - VA-HIT (diabetic sub group)

gemfibrozil vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
retinopathy	no data
vision loss	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with LDL elevation and without CHD: 1 trials - Helsinki (HHS)

gemfibrozil vs placebo

No demonstrated result

suggested Coronary event by 34% (not demonstrated)

suggested Non fatal MI by 37% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.66 [0.47 0.94]	p=0.04	0	4081	1	Helsinki (HHS),
Coronary death and non fatal MI	no data
Coronary death	0.73 [0.37 1.47]	p=1.00	0	4081	1	Helsinki (HHS),
cardiac death	0.73 [0.37 1.47]	p=1.00	0	4081	1	Helsinki (HHS),
MACE	no data
Non fatal MI	0.63 [0.43 0.92]	p=0.04	0	4081	1	Helsinki (HHS),
All cause death	1.02 [0.67 1.56]	p=1.00	0	4081	1	Helsinki (HHS),
non cardiovascular death	1.24 [0.72 2.13]	p=1.00	0	4081	1	Helsinki (HHS),
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.99 [0.43 2.30]	p=1.00	0	4081	1	Helsinki (HHS),
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with prior MI or with CHD: 3 trials - VA-HIT - HHS (Frick)(secondary prev subgroup) - LOCAT

gemfibrozil vs placebo

No demonstrated result

suggested cardiovascular events by 22% (not demonstrated)

suggested Coronary event by 20% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	0.78 [0.65 0.94]	p=0.04	0	2531	1	VA-HIT,
Cardiovascular death	no data
stroke (fatal and non fatal)	0.76 [0.54 1.09]	p=1.00	0	2531	1	VA-HIT,
Coronary event	0.80 [0.66 0.98]	p=0.04	0	2926	2	VA-HIT,LOCAT,
Coronary death and non fatal MI	no data
Coronary death	0.79 [0.59 1.05]	p=1.00	0	2531	1	VA-HIT,
cardiac death	0.87 [0.67 1.14]	p=1.00	0	3159	2	VA-HIT,HHS (Frick)(secondary prev subgroup),
MACE	no data
Non fatal MI	0.80 [0.63 1.00]	p=1.00	0	2531	1	VA-HIT,
All cause death	0.94 [0.77 1.15]	p=1.00	0	3159	2	VA-HIT,HHS (Frick)(secondary prev subgroup),
non cardiovascular death	1.08 [0.81 1.43]	p=1.00	0	3159	2	VA-HIT,HHS (Frick)(secondary prev subgroup),
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.88 [0.59 1.33]	p=1.00	0	2531	1	VA-HIT,
Rhabdomyolysis	no data
Myopathy	no data
Cancer	0.91 [0.70 1.17]	p=1.00	0	2531	1	VA-HIT,
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Diabetes type 2

Diabetic patients with or withour hypercholesterolemia: 2 trials - HHS (diabetic sub group) - VA-HIT (diabetic sub group)

gemfibrozil vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
retinopathy	no data
vision loss	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Primary prevention: 1 trials - HHS (diabetic sub group)

gemfibrozil vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
retinopathy	no data
vision loss	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Secondary prevention: 1 trials - VA-HIT (diabetic sub group)

gemfibrozil vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
retinopathy	no data
vision loss	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Post myocardial infarction

All type of patients: 1 trials - VA-HIT

gemfibrozil vs placebo

No demonstrated result

suggested cardiovascular events by 22% (not demonstrated)

suggested Coronary event by 20% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	0.78 [0.65 0.94]	p=0.04	0	2531	1	VA-HIT,
Cardiovascular death	no data
stroke (fatal and non fatal)	0.76 [0.54 1.09]	p=1.00	0	2531	1	VA-HIT,
Coronary event	0.80 [0.66 0.97]	p=0.04	0	2531	1	VA-HIT,
Coronary death and non fatal MI	no data
Coronary death	0.79 [0.59 1.05]	p=1.00	0	2531	1	VA-HIT,
cardiac death	0.79 [0.59 1.05]	p=1.00	0	2531	1	VA-HIT,
MACE	no data
Non fatal MI	0.80 [0.63 1.00]	p=1.00	0	2531	1	VA-HIT,
All cause death	0.90 [0.73 1.11]	p=1.00	0	2531	1	VA-HIT,
non cardiovascular death	1.10 [0.82 1.47]	p=1.00	0	2531	1	VA-HIT,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	0.88 [0.59 1.33]	p=1.00	0	2531	1	VA-HIT,
Rhabdomyolysis	no data
Myopathy	no data
Cancer	0.91 [0.70 1.17]	p=1.00	0	2531	1	VA-HIT,
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Gemfibrozil cholesterol lowering intervention

Atrial fibrillation

Cardiovascular prevention

Diabetes type 2

Post myocardial infarction